title: Relationship between prothrombin activation fragment F1 + 2 and serum cholesterol.
abstract: Plasma levels of fibrinogen, factor VIIc and prothrombin fragment F1 + 2, a marker of thrombin generation in vivo, were studied in 68 subjects with serum total cholesterol (TC) levels between 135 and 349 mg/dl but without clinical evidence of cardiovascular disease and other atherosclerotic risk factors. F1 + 2 plasma levels were directly correlated with TC (p < 0.0004), low-density lipoprotein cholesterol (LDL-C; p < 0.0018) and factor VIIc (p < 0.024). Thirty-five subjects with TC greater than 249 mg/dl (median value of the whole group) showed higher levels of F1 + 2 (p < 0.0001) and fibrinogen (p < 0.0015) than those with TC lower than 249 mg/dl. In subjects with TC > 249 mg/dl and F1 + 2 > 1.2 nM (median value of the whole group), a cholesterol-lowering drug (simvastatin) was able to reduce F1 + 2 (p < 0.009) as well as TC and LDL-C. This study shows a relationship between serum cholesterol and the rate of thrombin generation supporting the hypothesis that a hypercoagulable state may occur in hypercholesterolemic subjects before the onset of clinical evidence of atherosclerotic cardiovascular disease.
authors.affiliation: Istituto di Terapia Medica Sistematica, Università La Sapienza, Roma, Italia.
authors.forename: C
authors.initials: C
authors.lastname: Alessandri
authors.forename: S
authors.initials: S
authors.lastname: Basili
authors.forename: M
authors.initials: M
authors.lastname: Maurelli
authors.forename: D
authors.initials: D
authors.lastname: Bracaglia
authors.forename: P
authors.initials: P
authors.lastname: Andreozzi
authors.forename: M
authors.initials: M
authors.lastname: Pergolini
authors.forename: C
authors.initials: C
authors.lastname: Cordova
mesh_terms: D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000941:Antigens / Q000032:analysis; D002784:Cholesterol / Q000097:blood*; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003131:Combined Modality Therapy; D004041:Dietary Fats / Q000008:administration & dosage; D005167:Factor VII / Q000032:analysis; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy; D008148:Lovastatin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis*; D011516:Prothrombin / Q000032:analysis*; D019821:Simvastatin; D013917:Thrombin / Q000096:biosynthesis; D014280:Triglycerides / Q000097:blood
chemical_list: D000924:Anticholesteremic Agents; D000941:Antigens; D002791:Cholesterol, Dietary; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D004041:Dietary Fats; D010446:Peptide Fragments; D014280:Triglycerides; C042580:factor VII clotting antigen; C045879:prothrombin fragment 1.2; D005167:Factor VII; D011516:Prothrombin; D005340:Fibrinogen; D002784:Cholesterol; D008148:Lovastatin; D019821:Simvastatin; D013917:Thrombin